JP2013528655A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528655A5
JP2013528655A5 JP2013515492A JP2013515492A JP2013528655A5 JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5 JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5
Authority
JP
Japan
Prior art keywords
compound according
compound
xanthine oxidase
oxidase inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515492A
Other languages
English (en)
Japanese (ja)
Other versions
JP5551310B2 (ja
JP2013528655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040585 external-priority patent/WO2011159839A2/en
Publication of JP2013528655A publication Critical patent/JP2013528655A/ja
Publication of JP2013528655A5 publication Critical patent/JP2013528655A5/ja
Application granted granted Critical
Publication of JP5551310B2 publication Critical patent/JP5551310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515492A 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法 Active JP5551310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35549110P 2010-06-16 2010-06-16
US61/355,491 2010-06-16
PCT/US2011/040585 WO2011159839A2 (en) 2010-06-16 2011-06-15 Thioacetate compounds, compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014105611A Division JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法

Publications (3)

Publication Number Publication Date
JP2013528655A JP2013528655A (ja) 2013-07-11
JP2013528655A5 true JP2013528655A5 (enExample) 2014-05-15
JP5551310B2 JP5551310B2 (ja) 2014-07-16

Family

ID=45348850

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013515492A Active JP5551310B2 (ja) 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Country Status (41)

Country Link
US (5) US10266493B2 (enExample)
EP (5) EP2585437B1 (enExample)
JP (5) JP5551310B2 (enExample)
KR (2) KR101432950B1 (enExample)
CN (2) CN103068801B (enExample)
AR (1) AR081930A1 (enExample)
AU (1) AU2011268360B2 (enExample)
BR (1) BR112012032028B1 (enExample)
CA (1) CA2802535C (enExample)
CL (1) CL2012003546A1 (enExample)
CO (1) CO6640311A2 (enExample)
CR (1) CR20120649A (enExample)
CU (1) CU24126B1 (enExample)
CY (1) CY1120337T1 (enExample)
DK (3) DK2585437T3 (enExample)
DO (1) DOP2012000314A (enExample)
EA (1) EA022933B1 (enExample)
EC (1) ECSP12012353A (enExample)
ES (3) ES2551114T3 (enExample)
GT (1) GT201200339A (enExample)
HN (1) HN2012002664A (enExample)
HR (3) HRP20140391T1 (enExample)
HU (2) HUE025962T2 (enExample)
IL (2) IL223435A (enExample)
LT (1) LT2975025T (enExample)
ME (2) ME01830B (enExample)
MX (2) MX343583B (enExample)
MY (1) MY153039A (enExample)
PE (1) PE20131047A1 (enExample)
PH (1) PH12012502460A1 (enExample)
PL (3) PL2975025T3 (enExample)
PT (3) PT2585437E (enExample)
RS (3) RS57363B1 (enExample)
SG (2) SG186298A1 (enExample)
SI (3) SI2585437T1 (enExample)
SM (3) SMT201800304T1 (enExample)
TR (1) TR201808344T4 (enExample)
TW (2) TWI460173B (enExample)
UA (1) UA107115C2 (enExample)
WO (1) WO2011159839A2 (enExample)
ZA (1) ZA201209574B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CA2802692C (en) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
BR112014010495A2 (pt) * 2011-11-03 2017-04-25 Ardea Biosciences Inc composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo
NZ708031A (en) * 2012-11-14 2018-04-27 Teijin Pharma Ltd Pyridine derivative
PT2998296T (pt) 2013-05-13 2018-06-15 Shanghai hengrui pharmaceutical co ltd Derivado de ácido cicloalquilo, método de preparação do mesmo e suas aplicações fabmacêuticas
ES2784489T3 (es) * 2013-06-27 2020-09-28 Lg Chemical Ltd Derivados de biarilo como agonistas de GPR120
US9856237B2 (en) * 2014-05-13 2018-01-02 Teijin Pharma Limited Pyrazine derivatives
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途
CA2970011C (en) * 2014-12-24 2021-08-03 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
RU2721844C2 (ru) * 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
CN108026043A (zh) * 2015-08-14 2018-05-11 广东东阳光药业有限公司 一种萘环化合物的晶型
CN105418495B (zh) * 2015-11-25 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 一种硫醚的制备方法
US10450274B2 (en) * 2015-12-07 2019-10-22 Hinova Pharmaceuticals Inc. Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
WO2017114352A1 (en) 2015-12-28 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
US20210052547A1 (en) * 2016-02-15 2021-02-25 Institut National De La Sante Et De La Recherche Medicale (Nserm) Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
EP3538151B1 (en) 2016-11-11 2024-06-26 Whitehead Institute for Biomedical Research Human plasma-like medium
CN106748987B (zh) * 2016-11-18 2019-05-31 昆药集团股份有限公司 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型
BR112019011211A2 (pt) 2016-12-16 2019-10-15 Basf Se compostos de fórmula i, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento de ataque ou infestação por pragas invertebradas, semente, uso de um composto e método para tratar ou proteger um animal
CN106883169A (zh) * 2017-04-01 2017-06-23 浙江永宁药业股份有限公司 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用
WO2018202039A1 (zh) * 2017-05-03 2018-11-08 成都海创药业有限公司 杂环化合物及其制备方法
TW201922706A (zh) * 2017-10-04 2019-06-16 日商日本煙草產業股份有限公司 含氮雜芳基化合物及該化合物之醫藥用途
CN107955029B (zh) * 2017-12-07 2020-08-11 成都美域高制药有限公司 一种雷西纳德的制备方法
CN108069940B (zh) * 2017-12-20 2021-04-30 广东赛烽医药科技有限公司 硫代乙酸化合物、组合物及其应用
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN108440397B (zh) * 2018-03-06 2020-06-05 南方医科大学 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用
WO2019183835A1 (en) 2018-03-28 2019-10-03 Inventisbio Shanghai Ltd. Novel salt forms of urat-1 inhibitors
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
KR20220035156A (ko) 2019-07-16 2022-03-21 아스트라제네카 아베 베리누라드를 포함하는 과량 방출 저항성 약제학적 조성물
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
AR124985A1 (es) * 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
WO2022184977A1 (en) * 2021-03-01 2022-09-09 Orion Corporation Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
CN118439998A (zh) * 2021-05-19 2024-08-06 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
CN113979931B (zh) * 2021-10-08 2023-06-13 南方医科大学 一种吡啶3-胺衍生物及其制备方法和应用
CN114214361A (zh) * 2022-01-07 2022-03-22 中国农业科学院兰州兽医研究所 一种urat1人源化小鼠模型的构建方法及其应用
CN117362223A (zh) * 2023-09-14 2024-01-09 河北远征药业有限公司 一种4-巯基吡啶的制备方法
WO2025060752A1 (zh) * 2023-09-19 2025-03-27 湘北威尔曼制药股份有限公司 一种硫醚衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE642046A (enExample) * 1963-01-03
ES475100A1 (es) * 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE122008000051I1 (de) 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
CA2105617A1 (en) * 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
IL143929A0 (en) * 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
KR101241716B1 (ko) 2004-08-25 2013-03-08 아디아 바이오사이언스즈 인크. HIV 역 전사 효소의 억제제로서 S-트리아졸릴 α-메르캅토아세트아닐리드
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1896033A4 (en) 2005-06-15 2010-12-22 New York Blood Ct Inc ANTIVIRAL COMPOSITIONS WITH HETEROCYCLIC SUBSTITUTED PHENYLFURANES AND RELATED COMPOUNDS
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2328874A4 (en) 2008-09-04 2012-05-09 Ardea Biosciences Inc COMPOSITES, COMPOSITIONS AND METHOD FOR THEIR USE FOR MODULING THE HARNIC ACID MIRROR
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
US8372807B2 (en) 2009-05-20 2013-02-12 Ardea Biosciences, Inc. Methods of modulating uric acid levels
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス,インク. 尿酸値を調節するための化合物、組成物及び方法
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
CA2802692C (en) * 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112014010495A2 (pt) * 2011-11-03 2017-04-25 Ardea Biosciences Inc composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo

Similar Documents

Publication Publication Date Title
JP2013528655A5 (enExample)
HRP20140391T1 (hr) Spojevi i pripravci tioacetata, te postupci uporabe
JP2012184234A5 (enExample)
JP2014532726A5 (enExample)
JP2017524704A5 (enExample)
JP2014532647A5 (enExample)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2013528650A5 (enExample)
NO20070155L (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
JP2014012726A5 (enExample)
JP2017528503A5 (enExample)
JP2015508749A5 (enExample)
JP2011520965A5 (enExample)
JP2013087119A5 (enExample)
JP2016540749A5 (enExample)
PH12018500261A1 (en) Azole benzene derivative
JP2014532760A5 (enExample)
JP2016510326A5 (enExample)
JP2016520133A5 (enExample)
JP2017511377A5 (enExample)
JP2015521156A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
CY1124383T1 (el) Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας
JP2008513510A5 (enExample)
WO2008137809A3 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof